Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity

Klaus Pors, Paul M. Loadman, Steven D. Shnyder, Mark Sutherland, Helen M. Sheldrake, Meritxell Guinó, Konstantinos Kiakos, John A. Hartley, Mark Searcey, Laurence H. Patterson

Chemical Communications · 2011 · 42 citations · 25 references

Concepts

Abstract

The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.

References

25